We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Device Can ‘Read the Blood Through the Skin’ to Measure Hemoglobin in Real-Time

By LabMedica International staff writers
Posted on 02 Nov 2021

A team of bioengineers and scientists has developed a new noninvasive technology that may help real-time monitoring of key blood parameters, such as hemoglobin, especially in Black patients.

The wearable device developed by researchers at The University of Texas at Arlington (Arlington, TX, USA) in collaboration with Shani Biotechnologies, LLC, could reduce racial disparities in blood measurements. Most currently available methods for monitoring hemoglobin require blood samples and expensive equipment. The available noninvasive spectroscopic methods have a high degree of variability and often are inaccurate in people of color due to differences in skin melanin. There is a significant unmet need for a reliable, noninvasive device to estimate hemoglobin, irrespective of skin color.


Image: From left, Alexandra Hansard, Sanjay Gokhale and George Alexandrakis (Photo courtesy of The University of Texas at Arlington)
Image: From left, Alexandra Hansard, Sanjay Gokhale and George Alexandrakis (Photo courtesy of The University of Texas at Arlington)

The researchers came up with the idea of developing a wearable device, such as a watch or a monitor, “that would read the blood through the skin.” The new device relies on the spectroscopic properties of hemoglobin in the blue-green light spectra, as opposed to the red-infrared spectra currently used in similar devices. The device is easy to use, utilizing a probe that is placed on the skin and measures reflected light from the skin. The team evaluated the novel device in more than 30 participants. They compared the hemoglobin values measured by the device to those measured by currently available point-of-care devices, as well as through standard blood tests. Preliminary results suggest the device can estimate hemoglobin with better accuracy and consistency than currently available comparable methods.

“We are planning larger studies in a variety of patient populations to advance the clinical development of the device,” said Vinoop Daggubati, MD, CEO of Shani Biotechnologies. “The technology has massive potential in health care settings, remote monitoring and embodiment into wearables. We are committed to closing the racial disparity in these diagnostic modalities to provide better care for African Americans, Hispanics and people of color. Our technology is a steppingstone toward achieving that goal.”

Related Links:
The University of Texas at Arlington 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Latest Hematology News

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy